Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Patients with schizophrenia have an elevated mortality risk compared to the general population, with cardiovascular-related deaths being the leading cause. The role of clozapine use in the long-term mortality risk is unclear. While clozapine treatment may increase the risk for cardiovascular mortality, it may have protective effects regarding suicidal behavior. METHODS: We systematically searched EMBASE, MEDLINE, and PsycINFO and reviewed studies that used a long-term follow-up (ie, >52 weeks) and reported on mortality in adults diagnosed with schizophrenia-spectrum disorders who had received clozapine treatment. RESULTS: Altogether, 24 studies reported on 1327 deaths from any causes during 217691 patient years in patients treated with clozapine. The unadjusted mortality rate in 22 unique samples during a follow-up of 1.1-12.5 (median = 5.4) years was 6.7 (95% confidence interval [CI] = 5.4-7.9) per 1000 patient years. Long-term, crude mortality rate ratios were not significantly lower in patients ever treated with clozapine during follow-up, but significantly lower in patients continuously treated with clozapine compared to patients with other antipsychotics (mortality rate ratio = 0.56, 95% CI = 0.36-0.85, P-value = .007). Few studies reported on rates of long-term cause-specific mortality (suicide and ischemic heart disease), which showed no significant difference in patients using clozapine compared to patients using other antipsychotics. Statistical heterogeneity was high in all analyses. DISCUSSION: Continuous clozapine treatment in schizophrenia patients was associated with a significantly lower long-term all-cause mortality rate compared to other antipsychotic use. These findings, combined with the known efficacy of clozapine, give reason to re-evaluate the hesitancy to prescribe clozapine in regular care settings. TRIAL REGISTRATION: PROSPERO CRD42017069390.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, this study reported no difference in the rates of suicide in the two treatment arms, although the total number of deaths was relatively small (5 with clozapine and 3 with olanzapine).”
From Suicide and suicide risk (2019) · cites this paper as [304]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is indicated in schizophrenia, in which the lifetime rate of suicide deaths of patients is ~10% with ~50% of individuals attempting suicide 304 .”
From Suicide and suicide risk (2019) · cites this paper as [304]
Experimental — accuracy not yet measuredIn the citing paper
“Because both medications reduce the risk of suicidal behavior independently of how effective they are for mood and psychosis (225), this indicates potential effects via the diathesis.”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [224]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · doi:10.1002/9780470743386 · Cited by 14,225
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021) · doi:10.1002/9781119558378 · Cited by 9,799
Walker, E. R., McGee, R. E., & Druss, B. G. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2502 · Cited by 2,976
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Self-citationRisks of all-cause and suicide mortality in mental disorders: a meta-review
Chesney, E., Goodwin, G. M., & Fazel, S. (2014) · World Psychiatry · doi:10.1002/wps.20128 · Cited by 2,115
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Stringhini, S., Carmeli, C., Jokela, M., Avendaño, M., Muennig, P., Guida, F., Ricceri, F., d'Errico, A., Barros, H., Bochud, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32380-7 · Cited by 1,319
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Self-citationPremature Mortality Among Adults With Schizophrenia in the United States
Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1737 · Cited by 1,083
DE HERT, M., COHEN, D., BOBES, J., CETKOVICH‐BAKMAS, M., LEUCHT, S., NDETEI, D. M., NEWCOMER, J. W., UWAKWE, R., ASAI, I., MÖLLER, H., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00036.x · Cited by 870
Self-citationChang, C.-K., Hayes, R. D., Perera, G., Broadbent, M. T. M., Fernandes, A. C., Lee, W. E., Hotopf, M., & Stewart, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019590 · Cited by 714
Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 601
Siskind, D., Siskind, V., & Kisely, S. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717718167 · Cited by 391
Mortality in Current and Former Users of Clozapine
Walker, A. M., Lanza, L. L., Arellano, F., & Rothman, K. J. (1997) · Epidemiology · doi:10.1097/00001648-199710000-00010 · Cited by 328
International trends in clozapine use: a study in 17 countries
Bachmann, C. J., Aagaard, L., Bernardo, M., Brandt, L., Cartabia, M., Clavenna, A., Coma Fusté, A., Furu, K., Garuoliené, K., Hoffmann, F., et al. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12742 · Cited by 314
Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2955 · Cited by 300
Suicidal risk during treatment with clozapine: a meta-analysis
Hennen, J., & Baldessarini, R. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.015 · Cited by 287
Active monitoring of 12760 clozapine recipients in the UK and Ireland: Beyond pharmacovigilance
Munro, J., O'Sullivan, D., Andrews, C., Arana, A., Mortimer, A., & Kerwin, R. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.6.576 · Cited by 285
The history of clozapine and its emergence in the US market: a review and analysis
Crilly, J. (2007) · History of Psychiatry · doi:10.1177/0957154x07070335 · Cited by 272
Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
Taipale, H., Mittendorfer-Rutz, E., Alexanderson, K., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.12.010 · Cited by 262
Hennessy, S., Bilker, W. B., Knauss, J. S., Margolis, D. J., Kimmel, S. E., Reynolds, R. F., Glasser, D. B., Morrison, M. F., & Strom, B. L. (2002) · BMJ · doi:10.1136/bmj.325.7372.1070 · Cited by 261
Mortality in Current and Former Users of Clozapine
Walker, A. M., Lanza, L. L., Arellano, F., & Rothman, K. J. (1997) · Epidemiology · doi:10.1097/00001648-199711000-00014 · Cited by 239
Nielsen, J., Correll, C. U., Manu, P., & Kane, J. M. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08064 · Cited by 232
Self-citationEstimating the consequences of anti-psychotic induced weight gain on health and mortality rate
Fontaine, K. R., Heo, M., Harrigan, E. P., Shear, C. L., Lakshminarayanan, M., Casey, D. E., & Allison, D. B. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00234-7 · Cited by 230
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224
Psychiatrists’ attitude towards and knowledge of clozapine treatment
Nielsen, J., Dahm, M., Lublin, H., & Taylor, D. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108100320 · Cited by 213
Antipsychotic treatment and mortality in schizophrenia.
Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Bjorkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu164 · Cited by 208
Henderson, D. C., Nguyen, D. D., Copeland, P. M., Hayden, D. L., Borba, C. P., Louie, P. M., Freudenreich, O., Evins, A. E., Cather, C., & Goff, D. C. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0905 · Cited by 205
Worldwide Differences in Regulations of Clozapine Use
Nielsen, J., Young, C., Ifteni, P., Kishimoto, T., Xiang, Y.-T., Schulte, P. F. J., Correll, C. U., & Taylor, D. (2016) · CNS Drugs · doi:10.1007/s40263-016-0311-1 · Cited by 182
Self-citationMortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia
Wimberley, T., MacCabe, J. H., Laursen, T. M., Sørensen, H. J., Astrup, A., Horsdal, H. T., Gasse, C., & Støvring, H. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091097 · Cited by 136
Vermeulen, J., van Rooijen, G., Doedens, P., Numminen, E., van Tricht, M., & de Haan, L. (2017) · Psychological Medicine · doi:10.1017/s0033291717000873 · Cited by 134
Self-citationHayes, R. D., Downs, J., Chang, C.-K., Jackson, R. G., Shetty, H., Broadbent, M., Hotopf, M., & Stewart, R. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu120 · Cited by 128
Mortality Rates After the First Diagnosis of Psychotic Disorder in Adolescents and Young Adults
Simon, G. E., Stewart, C., Yarborough, B. J., Lynch, F., Coleman, K. J., Beck, A., Operskalski, B. H., Penfold, R. B., & Hunkeler, E. M. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4437 · Cited by 122
Binder, M. D., Correll, C. U., & Cohen, D. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.029 · Cited by 112
Self-citationTaylor, D. M., Douglas-Hall, P., Olofinjana, B., Whiskey, E., & Thomas, A. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051979 · Cited by 102
Kelly, D. L., McMahon, R. P., Liu, F., Love, R. C., Wehring, H. J., Shim, J.-C., Warren, K. R., & Conley, R. R. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04718yel · Cited by 90
Therapeutic Drug Monitoring of Clozapine in Relapse Prevention: A Five-Year Prospective Study
Gaertner, I., Gaertner, H. J., Vonthein, R., & Dietz, K. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00010 · Cited by 90
Kiviniemi, M., Suvisaari, J., Koivumaa-Honkanen, H. T., Häkkinen, U., Isohanni, M. K., & Hakko, H. H. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.043 · Cited by 86
Ringbäck Weitoft, G., Berglund, M., Lindström, E. A., Nilsson, M., Salmi, P., & Rosén, M. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3567 · Cited by 77
Discontinuation of clozapine: a 15‐year naturalistic retrospective study of 320 patients
Davis, M. C., Fuller, M. A., Strauss, M. E., Konicki, P. E., & Jaskiw, G. E. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12233 · Cited by 76
Girgis, R. R., Phillips, M. R., Li, X., Li, K., Jiang, H., Wu, C., Duan, N., Niu, Y., & Lieberman, J. A. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.081471 · Cited by 71
Clozapine and incidence of myocarditis and sudden death – Long term Australian experience
Khan, A. A., Ashraf, A., Baker, D. W., Al-Omary, M. S., Savage, L., Ekmejian, A. A., Singh, R., Brienesse, S. C., Majeed, T., Gordon, T., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.013 · Cited by 64
Sudden Death in Patients Receiving Clozapine Treatment: A Preliminary Investigation
Modai, I., Hirschmann, S., Rava, A., Kurs, R., Barak, P., Lichtenberg, P., & Ritsner, M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00006 · Cited by 59
Lindstr�m, L. H. (1989) · Psychopharmacology · doi:10.1007/bf00442567 · Cited by 48
Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia
Pridan, S., Swartz, M., Baruch, Y., Tadger, S., Plopski, I., & Barak, Y. (2014) · International Psychogeriatrics · doi:10.1017/s1041610214001756 · Cited by 36
Antipsychotic medication and long-term mortality risk in patients with schizophrenia
Vermeulen, J. M., van Rooijen, G., Doedens, P., Numminen, E., van Tricht, M. J., & de Haan, L. (2017) · Cited by 30
Self-citationHospital Days in Clozapine-Treated Patients
Dickson, R. A., Dalby, J. T., Williams, R., & Warden, S. J. (1998) · The Canadian Journal of Psychiatry · doi:10.1177/070674379804300911 · Cited by 25
Lee, J., Bies, R. R., Bhaloo, A., Powell, V., & Remington, G. J. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09143 · Cited by 16
A three-year naturalistic follow-up of patients receiving clozapine: Report from India
Srivastava, S., Agarwal, A., & Sharma, M. (2002) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/136515002760276108 · Cited by 16
Schulte, P. F. J., Bocxe, J. T. H., Doodeman, H. J., van Haelst, I. M. M., & Cohen, D. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000465 · Cited by 14
Rimón, R., Kuoppasalmi, K. I., Naukkarjnen, H., Lang, S., Sandqvist, A., & Leinonen, E. V. J. (1994) · Nordic Journal of Psychiatry · doi:10.3109/08039489409081367 · Cited by 12
Clozapine's Effect on Recidivism Among Offenders with Mental Disorders.
Mela, M., & Depiang, G. (2016) · PubMed · Cited by 11
Clozapine Reduces All-Cause Mortality
Kane, J. M. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17070770 · Cited by 10
Cited by
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Self-citationTurecki, G., Brent, D. A., Gunnell, D., O’Connor, R. C., Oquendo, M. A., Pirkis, J., & Stanley, B. H. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0121-0 · Cited by 1,074
Correll, C. U., Solmi, M., Croatto, G., Schneider, L. K., Rohani‐Montez, S. C., Fairley, L., Smith, N., Bitter, I., Gorwood, P., Taipale, H., et al. (2022) · World Psychiatry · doi:10.1002/wps.20994 · Cited by 686
Self-citationTaipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tiihonen, J. (2020) · World Psychiatry · doi:10.1002/wps.20699 · Cited by 415
Self-citationKnipe, D., Padmanathan, P., Newton-Howes, G., Chan, L. F., & Kapur, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00173-8 · Cited by 331
Metadata
- Authors
- Vermeulen, J. M., van Rooijen, G., van de Kerkhof, M. P. J., Sutterland, A. L., Correll, C. U., & de Haan, L.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Department of Psychiatry, Academic Medical Center, University of Amsterdam, Meibergdreef, AZ Amsterdam, The Netherlands
- Northwell Health (US)
- Corresponding author
- Vermeulen, Jentien M
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-25
- Volume
- 45
- Issue
- 2
- Pages
- 315-329
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC6403051
- OpenAlex
- W2800034999
- Cited by
- 246
- References
- 62
- Citations by year
- 2026: 27 · 2025: 35 · 2024: 34 · 2023: 30 · 2022: 30 · 2021: 30 · 2020: 31 · 2019: 24 · 2018: 5
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Schizophrenia Bulletin (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- clozapine, schizophrenia
- MeSH terms
- Clozapine, Humans, Schizophrenia, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.